About
Pipeline & Research
NEWS & MEDIA
Investors
Careers
Contact Us

Select Page

H.C. Wainwright 22nd Annual Global Investment Conference

September 14, 2020

09.14.2020

H.C. Wainwright 22nd Annual Global Investment Conference

Search for:

RECENT NEWS ARTICLES

BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
BeyondSpring to Participate in the William Blair Biotech Focus Conference
BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors
BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

RECENT MEDIA COVERAGE

TD Ameritrade Watch List
Managing Chemotherapy Toxicities for Improved Patient Outcomes
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
Seed Therapeutics blossoms in an $800M deal with Lilly
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring

WORK WITH US

LifeSci Advisors

Investor Contact
Ashley R. Robinson
+1 617-430-7577
arr@lifesciadvisors.com

Media Contact
Darren Opland, Ph.D.
+1 646-627-8387
darren@lifescicomms.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

GET UPDATES

Subscribe to BeyondSpring News & Media!

Who We Are
Management Team
Scientific Advisors
Board of Directors

PIPELINE & RESEARCH

Pipeline Overview
Plinabulin
Protein Degradation
Other Pipeline
Posters & Publications
Collaboration
Expanded Access Policy

Stock Overview
Events & Presentations
Financials & Filings
Corporate Governance

Job Opportunities

NEWS & MEDIA

Press Releases
Media Coverage

BeyondSprings Inc LinkedIn

BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved. Privacy Notice | Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.Ok Privacy policy